Nutriband INC

Nutriband Inc. has selected a commercial brand name for its abuse-deterrent fentanyl transdermal system and plans to submit it to regulatory agencies for approval.

Nutriband Inc. has terminated its agreement to sell subsidiary Pocono Pharmaceuticals, Inc. to Earth Vision Bio Inc. due to the buyer's failure to pay late fees.

Nutriband, Inc. announced shareholder approval of all proposals at its 2026 Annual Meeting, including the election of directors and an increase in authorized preferred stock.

Nutriband Inc. announced the sale of a 90% interest in its subsidiary Pocono Pharmaceutical for $5 million USD to EarthVision Bio, retaining a 10% stake in EarthVision Bio.

Nutriband Inc. announced successful feedback from the U.S. FDA on its AVERSA FENTANYL abuse-deterrent patch, paving the way for an Investigational New Drug (IND) filing.

Nutriband Inc. announced the exercise of stock options and warrants, generating over $5.3 million in proceeds and issuing 845,172 new shares between February and July 2025.

Nutriband Inc. reported a decrease in revenue for the first quarter of fiscal year 2026, primarily due to a major customer relocating operations, while also noting a reduction in net loss compared to the prior year.

Nutriband Inc. reported a significantly wider net loss for the three and nine months ended October 31, 2025, driven by increased expenses and a preferred stock dividend, despite an increase in cash and working capital.

Nutriband Inc. reported increased revenue and cash for the second quarter of 2025, alongside significant progress in its AVERSA Fentanyl development and a substantial preferred stock dividend.

Nutriband Inc. announced a narrower net loss and increased revenue for the quarter ended April 30, 2025, driven by growth in its contract manufacturing segment, despite continued cash burn and ongoing reliance on external financing for its AVERSA drug development pipeline.

Nutriband Inc. saw a revenue increase and a reduction in net losses for the quarter ended October 31, 2024, supported by recent equity financing.

Nutriband Inc. reported a widened net loss for the quarter ended July 31, 2024, despite a significant equity financing round.

Nutriband Inc. has filed an amendment to its 2026 Form 10-K to include its Executive Compensation Clawback Policy, adopted in compliance with NASDAQ listing standards and SEC Rule 10D-1.

Nutriband Inc. filed its annual report for the fiscal year ended January 31, 2026, detailing progress on its AVERSA Fentanyl abuse-deterrent transdermal system and financial performance from its contract manufacturing segment.

Nutriband Inc. has filed an amendment to its annual report on Form 10-K for the fiscal year ended January 31, 2025, with updated exhibits and certifications.

Nutriband Inc.'s 10-K filing reveals a widened net loss for fiscal year 2025, driven by increased research and development expenses for its AVERSA Fentanyl product and an impairment charge, despite a slight revenue increase.

Nutriband Inc. files its annual report, detailing financial results and progress in developing its AVERSA abuse-deterrent transdermal technology.

NutriBand's Chief Financial Officer, Gerald Goodman, has reported the acquisition of stock options and the disposition of stock warrants.

NutriBand Inc.'s President and Secretary, Serguei Melnik, acquired 97,500 options to purchase common stock at an exercise price of $2.61 on March 20, 2024.

NutriBand Inc.'s CEO, Gareth Sheridan, acquired 75,000 options to purchase common stock at an exercise price of $2.37 per share.

Nutriband Inc. announces its 2026 Annual Meeting of Stockholders to address director elections, auditor ratification, executive compensation, and a proposed increase in authorized preferred stock.

Serguei Melnik, President of Nutriband Inc., has filed a Schedule 13D with the SEC, disclosing beneficial ownership of 9.39% of the company's common stock.

Nutriband Inc.'s CEO, Gareth Sheridan, has filed a Schedule 13D disclosing a beneficial ownership of 17.73% of the company's common stock, held for investment purposes and including founder's shares and unexercised stock options.